skip to Main Content
Phone: 301-655-1084 Email: info@glycomantra.com

Our Team

Hafiz Ahmed, Ph.D.
Founder, President & CEO

Elizabeth Smith, Ph.D., MBA
Executive Director of Partnering and Strategy

Khairul Anam, Ph.D.
Chief Operating Officer

Our Advisors

Dr. Gerardo R. Vasta, Ph.D.
Professor of Microbiology and Immunology

Dr. Dhan V. Kalvakolanu, Ph.D.
Professor of Microbiology and Immunology

Dr. Arif Hussain, M.D.
Professor of Medicine

Dr. Charles Bieberich, Ph.D.
Professor of Biological Sciences

Dr. Saranya Chumsri, M.D.
Assistant Professor of Medicine

Dr. Channing J. Paller, M.D.
Assistant Professor of Oncology

Dr. Larry Loomis, Ph.D.
President, New Horizons Diagnostics, Baltimore

Our Team

Hafiz Ahmed, Ph.D.
Founder, President & CEO

 Dr. Ahmed is an experienced scientist and prior faculty member at the University of Maryland, Baltimore (UMB). He is an expert in protein chemistry, oncology/onco-immunology and glycobiology, particularly protein-carbohydrate interactions in cancer. Over the last five years, he implemented both short and long-term strategic R&D programs which led to the identification of a high affinity glycopeptide – a promising anti-metastatic agent for the treatment of various cancers, including prostate adenocarcinoma. He founded GlycoMantra, Inc. based on this technology and has continued the discovery and pre-clinical development program on a commercial pathway. He is passionate about this technology and remains the driving force behind the program. Dr. Ahmed has published over 80 peer-reviewed original articles in high impact journals including PNAS, Biomaterials, Journal of Immunology, Oncotarget, and JBC. He authored a book on protein techniques, edited “Glycobiology of Cancer”, and co-edited a book on animal lectins. He is a lead inventor of 5 US patents and is currently serving as editorial board member of 5 journals and reviewer of many reputed journals. He has served as PI of seven grants (federal and state) and secured over $4 Million as PI/Co-PI.

Elizabeth Smith, Ph.D., MBA
Executive Director of Partnering and Strategy

 Dr. Smith has over 15 years experience assisting biotech companies in corporate business development activities. At Celsion, an oncology therapeutics company, she led the ThermoDox®+ MRgHIFU non-clinical program for metastatic bone pain palliation in partnership with Philips Healthcare. This was the first ever non-approved Drug-Device combination to receive phase II IND clearance from the FDA. At Celsion, she also strategically managed the intellectual property portfolio, grants programs, the scientific advisory board and in-licensing opportunities. Before Celsion, she worked for 5 years in The University of Chicago technology transfer office where she managed out-licensing and start-up efforts for over 30 patent portfolios from The Division of Biological Sciences. Through SoMax Consulting, she currently works with many start-ups in the Maryland biotechnology incubator system and is a preferred provider at the Germantown Innovation Center, the Frederick Innovative Technology Center and bwtech@UMBC Research & Technology Park. She is a member of the TEDCO Maryland Entrepreneurial Resource List, and grant reviewer for NIH SBIR/STTR Commercialization Readiness Pilot (CRP) and previous corporate partner and reviewer for the Invest Maryland Challenge. She is a mentor for the Freedom from Cancer Startup Challenge. Dr. Smith has written over two-dozen pharmaceutical and biotechnology commercialization plans and has helped to secure over $10 Million in non-dilutive funding.

Khairul Anam, Ph.D.
Chief Operating Officer

 Dr. Anam has extensive expertise in immunology and stem cell therapy, and over 18 years of research experience with a focus on vaccine development, stem cell mediated immunomodulation and wound healing. In his prior position at the Navy Medical Research Center, he successfully wrote grants and secured $1.5 Million as a Co-PI. He has mentored several research projects involving immunomodulation and produced over 25 peer-reviewed publications. At GlycoMantra, he successfully completed an NIH-NCI funded SBIR project and participated the NIH I-CORPS program with Dr. Ahmed. He manages GlycoMantra’s drug development programs in cancer and fibrosis.

Our Advisors

Dr. Gerardo R. Vasta, Ph.D.
Professor of Microbiology and Immunology
University of Maryland School of Medicine, Baltimore and
Institute of Marine and Environmental Technology, Baltimore

Expert in protein-carbohydrate interactions of infection, immunity and early development. [see Profile]

 

Dr. Dhan V. Kalvakolanu, Ph.D.
Professor of Microbiology and Immunology
Greenebaum Cancer Center
University of Maryland School of Medicine, Baltimore

Expert in signal transduction by cytokines, tumor cell growth control and apoptosis. [see Profile]

 

Dr. Arif Hussain, M.D.
Professor of Medicine
Greenebaum Cancer Center
University of Maryland School of Medicine, Baltimore

Expert in genito-urinary malignancies and clinical trials in prostate and bladder cancers. [see Profile]

 

Dr. Charles Bieberich, Ph.D.
Professor of Biological Sciences
University of Maryland, Baltimore County

Expert in developmental biology, tumor suppressor, and mouse models of metastatic prostate cancer. [see Profile]

 

Dr. Saranya Chumsri, M.D.
Assistant Professor of Medicine
Greenebaum Cancer Center
University of Maryland School of Medicine, Baltimore

Expert in translational research and clinical trial of breast cancer. [see Profile]

 

Dr. Channing J. Paller, M.D.
Assistant Professor of Oncology
Sidney Kimmel Comprehensive Cancer Center
Johns Hopkins University School of Medicine, Baltimore

Expert in translational research and clinical trials of developmental therapeutics in prostate and other solid tumors. [see Profile]

 

Dr. Larry Loomis, Ph.D.
President
New Horizons Diagnostics, Baltimore

Expert in infectious diseases and in the development of rapid detection of bacteria and toxins in human, environmental, surface, food, and water samples. [see Profile]

Back To Top